Eating Too Little on a GLP-1: What the Deficiency Data Show

The drug is supposed to make you eat less. The problem is that it does not distinguish between eating less and eating badly, and the evidence suggests most people end up doing both. Pooling six studies covering 480,825 adults, more than 60% of GLP-1 users were consuming below estimated requirements, vitamin D deficiency reached 13.6% by twelve months, and ferritin ran 26–30% below an active comparator.^[1] That is not a fringe risk. It is the majority experience.

Why appetite suppression does this

Three mechanisms stack, and the review names all three: appetite suppression, delayed gastric emptying, and altered absorption.^[1] Eating less means less of everything, not less of the surplus — the body does not preferentially discard the calories you did not need.

There is a second, subtler problem. When appetite is low, the foods people keep are usually the easy ones. Protein-dense and fiber-dense foods feel heaviest and get dropped first, which is exactly backwards for anyone trying to protect muscle and bowel function while losing weight.

What is actually running low

The iron figure is worth pausing on because of what it is compared against. These are not people measured against the healthy general population — they are measured against others taking a different drug for the same conditions, which strips out a lot of confounding. A 26–30% gap in that comparison is a real difference attributable to something about this therapy.

Low iron and low vitamin D both produce fatigue, which is one reason our fatigue article lists them as the first things worth checking rather than assuming the drug is doing it directly.

The rare end, and why it is here

Wernicke encephalopathy is acute brain injury caused by thiamine deficiency. It presents with confusion, abnormal eye movements and unsteadiness, it is a medical emergency, and it is largely reversible if treated quickly and not if it is not.

A 2025 analysis gathered a case in a 49-year-old woman on semaglutide alongside eighteen others from the literature and the World Health Organization’s VigiBase, and ran a disproportionality analysis. Wernicke encephalopathy was disproportionately reported with semaglutide, with tirzepatide, and with the GLP-1 class as a whole. In 68% of cases there was vomiting or reduced food intake, with weight loss running from 3.5 to 13.3 kg per month.^[2]

Nineteen cases against many millions of prescriptions. The mechanism, though, is exactly what these drugs produce.

That proportion belongs in any honest account of this. It is rare. It is included here because thiamine deficiency is cheap to prevent, because the risk factors are the ordinary side effects of the drug rather than anything exotic, and because the authors describe their own finding as a safety signal requiring prompt assessment.^[2]

How much weight loss is too fast

The Wernicke cases ran between 3.5 and 13.3 kg a month.^[2] For context, the pivotal trials averaged roughly 15% of body weight over 68 weeks — a far slower rate. Losing weight much faster than the trials produced is not evidence the drug is working better; it is usually evidence of intake low enough to matter.

Rapid loss also drives the other risks this site covers with their own evidence: gallstones, where the label notes the excess persisted even after adjusting for how much weight came off, and lean mass.

What to do about it

• Eat to a target, not to appetite. Appetite is the thing the drug has switched off, which makes it a broken instrument for deciding how much to eat. Our protein and fiber calculators give numbers to aim at.
• Ask for bloods rather than assuming. Vitamin D, ferritin and B12 are cheap, routine, and the ones this evidence points at.
• Treat persistent vomiting as urgent rather than expected. It is the common thread in the severe cases, and it also drives the dehydration behind the acute kidney injury the label warns about.
• Do not take supplementation as read. A multivitamin is reasonable, but no trial has shown which regimen prevents these specific deficiencies on these specific drugs, and a prescriber who measures beats a guess.